HUP0101012A3 - Pharmaceutical composition for oral administration - Google Patents

Pharmaceutical composition for oral administration

Info

Publication number
HUP0101012A3
HUP0101012A3 HU0101012A HUP0101012A HUP0101012A3 HU P0101012 A3 HUP0101012 A3 HU P0101012A3 HU 0101012 A HU0101012 A HU 0101012A HU P0101012 A HUP0101012 A HU P0101012A HU P0101012 A3 HUP0101012 A3 HU P0101012A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
oral administration
oral
administration
pharmaceutical
Prior art date
Application number
HU0101012A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HUP0101012A2 publication Critical patent/HUP0101012A2/hu
Publication of HUP0101012A3 publication Critical patent/HUP0101012A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
HU0101012A 1997-12-24 1998-12-14 Pharmaceutical composition for oral administration HUP0101012A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9716529A FR2772614B1 (fr) 1997-12-24 1997-12-24 Solution aqueuse a base de chlorhydrate de 1- [ 2-(2-naphtyl)ethyl]-4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine et composition pharmaceutique buvable en contenant
PCT/FR1998/002712 WO1999033466A1 (fr) 1997-12-24 1998-12-14 Composition pharmaceutique buvable

Publications (2)

Publication Number Publication Date
HUP0101012A2 HUP0101012A2 (hu) 2001-08-28
HUP0101012A3 true HUP0101012A3 (en) 2002-12-28

Family

ID=9515152

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101012A HUP0101012A3 (en) 1997-12-24 1998-12-14 Pharmaceutical composition for oral administration

Country Status (25)

Country Link
US (1) US6191137B1 (hu)
EP (1) EP1041984B1 (hu)
JP (1) JP2002510599A (hu)
AR (1) AR017722A1 (hu)
AT (1) ATE252384T1 (hu)
AU (1) AU1880599A (hu)
BR (1) BR9814414A (hu)
CA (1) CA2315696C (hu)
CO (1) CO4970813A1 (hu)
DE (1) DE69819203T2 (hu)
DK (1) DK1041984T3 (hu)
DZ (1) DZ2676A1 (hu)
ES (1) ES2209238T3 (hu)
FR (1) FR2772614B1 (hu)
GT (1) GT199800204A (hu)
HU (1) HUP0101012A3 (hu)
MY (1) MY117156A (hu)
NO (1) NO20003284L (hu)
PT (1) PT1041984E (hu)
SA (2) SA99191003B1 (hu)
SI (1) SI1041984T1 (hu)
TW (1) TW536409B (hu)
UY (1) UY25320A1 (hu)
WO (1) WO1999033466A1 (hu)
ZA (1) ZA9811824B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.

Also Published As

Publication number Publication date
DE69819203D1 (de) 2003-11-27
TW536409B (en) 2003-06-11
NO20003284D0 (no) 2000-06-22
AU1880599A (en) 1999-07-19
CO4970813A1 (es) 2000-11-07
ZA9811824B (en) 1999-06-29
CA2315696A1 (en) 1999-07-08
ES2209238T3 (es) 2004-06-16
DK1041984T3 (da) 2004-02-16
DZ2676A1 (fr) 2004-09-19
MY117156A (en) 2004-05-31
DE69819203T2 (de) 2004-07-15
SI1041984T1 (en) 2004-04-30
FR2772614B1 (fr) 2000-03-10
GT199800204A (es) 2000-06-14
EP1041984A1 (fr) 2000-10-11
FR2772614A1 (fr) 1999-06-25
US6191137B1 (en) 2001-02-20
BR9814414A (pt) 2000-10-10
SA99191002B1 (ar) 2006-03-07
AR017722A1 (es) 2001-09-12
HUP0101012A2 (hu) 2001-08-28
PT1041984E (pt) 2004-02-27
EP1041984B1 (fr) 2003-10-22
WO1999033466A1 (fr) 1999-07-08
SA99191003B1 (ar) 2006-10-02
JP2002510599A (ja) 2002-04-09
NO20003284L (no) 2000-08-24
CA2315696C (en) 2008-01-29
UY25320A1 (es) 2000-10-31
ATE252384T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
IL115097A0 (en) Pharmaceutical compositions adapted for oral administration
EP0873749A4 (en) GELLED PRODUCTS FOR ORAL ADMINISTRATION
IL136827A0 (en) Oral pharmaceutical extended release dosage form
AU7375598A (en) Stable oral pharmaceutical dosage forms
IL117728A0 (en) Pharmaceutical compositions for transdermal administration
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
IL117041A0 (en) Oral pharmaceutical dosage form
PL322579A1 (en) 2-methyl-thiene-benzodiazeoin prparation for oral administration
PL334100A1 (en) Cyclosporin containing compositions for oral administration
IL145559A0 (en) Tolperison-containing pharmaceutical preparation for oral administration
HK1015677A1 (en) Rapamycin formulations for oral administration
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
HU9500618D0 (en) Oral pharmaceutical compositions
EP0953359A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HUP0003341A3 (en) Rapamycin formulations for oral administration
AU3860797A (en) Pharmaceutical formulations for oral administration
PL325509A1 (en) Therapeutic agent for oral administration
HUP0101012A3 (en) Pharmaceutical composition for oral administration
ZA974125B (en) Oral pharmaceutical compositions
EP1188440A4 (en) MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
GB9418029D0 (en) Pharmaceutical compositions for oral administration
SI0927031T1 (en) Pharmaceutical preparation containing nimesulide for oral administration
GB9711046D0 (en) Oral pharmaceutical compositions
ZA976144B (en) Oral pharmaceutical compositions
SI1043976T1 (sl) Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished